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Immunotherapy, Improving the Odds
Kristy Richards works with immunotherapies—especially monoclonal antibody therapies—
aiming to make them effective for cancer patients—dogs and people.

by Caitlin Hayes
In August 2015, former President Jimmy Carter announced that he had cancer that had
spread to his brain. By December of that year—after a combination of radiation, surgery,
and a new immunotherapy—doctors found no traces of the disease, and Carter was
deemed cancer-free. The immunotherapy doctors gave him triggered his own immune
system to fight against the cancer, a fight he seems to be winning.
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For select patients, immunotherapies have shown dramatic results such as this, but many
others don’t respond. Kristy L. Richards, Biomedical Sciences, wants to make
immunotherapies work for more patients. With a joint appointment in Hematology and
Medical Oncology at Weill Cornell Medicine, she studies lymphoma, why some patients with
the cancer respond to immunotherapies and others don’t, as well as which combination of
treatments could improve survival.
One research challenge Richards and other immuno-oncologists face is that the human
immune system is impossible to replicate in a dish. Richards’ answer has been to develop
clinical trials in dogs—pet dogs already diagnosed with lymphoma. Not only do the dogs
stand to benefit but also the pace and efficacy of drug development. Richards says that
with a $2.6 billion price tag and as much as a 20-year timeline to develop a new drug,
accelerating the process and lowering costs is imperative for patients and society. 
“Dogs eat dirt. They lick the floor. Their immune systems are really challenged,” Richards
says. “They live in our environment and are challenged by the same things as us, in
general.”  
Mouse models, on the other hand, are kept in a sterile environment, where their immune
systems remain underdeveloped. Dogs are also more genetically similar to humans, and the
way tumors arise in pet dogs more closely resembles human tumors’ spontaneous growth.
For sick dogs and their owners, the clinical trials have many benefits. The dogs get treated
with more attention, and owners have a treatment option if they couldn’t otherwise afford
one. Dogs also can’t tolerate high doses of chemotherapy, and the low doses they can
handle almost never cure them. Having a nontoxic option provides another avenue for
prolonged life.
“I love that dogs benefit,” Richards says. “And once we show that a chemo-free regimen
works in dogs, then we can make a better guess about how it’ll work in humans.”
One of the immunotherapies that Richards plans to test in dogs involves monoclonal
antibodies. These are proteins that can recognize cancerous cells and flag them for the
immune system to attack. Richards is currently experimenting with various antibodies to see
which will work best for lymphoma and why.
A longstanding effort in Richards’ lab has been to understand and improve a popular
monoclonal antibody prescribed for human patients with lymphoma, called rituximab.
Exceptionally Challenged Immune Systems
Monoclonal Antibody Therapies
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Rituximab has increased survival rates in the most common lymphoma subtype by 15
percent, from 50 percent survival before rituximab to 65 percent after. “It was really a
blockbuster drug,” Richards says. But because it quickly became so widely used, given in
combination with every chemotherapy regimen, little is known about why certain people
respond and others don’t.
Richards is studying a polymorphism that may provide one piece of the puzzle. Eventually,
she would like to identify and develop a biomarker and assay that could be used to predict
a patient’s response to rituximab. At around $20,000 for a course of the drug, this test could
save patients and taxpayers money, while also shedding light on the 35 percent of patients
with resistance.
Some of the other immunotherapies Richards works on could be straight out of science
fiction. One is based on immune checkpoint inhibitors, the type Carter received, which take
the brakes off of the immune system. This makes the immune system more sensitive and
therefore more aggressive.
Another therapy involves the making of CAR (Chimeric Antigen Receptor) T cells, where a
monoclonal antibody is inserted into a T cell, one of the body’s immune cells. The antibody
is expressed on the surface of the T cell, where it can find and bind to cancer cells, bringing
the T cell with it. “This takes the immune system to the cancer cell and activates the T cell,
so it’s basically like a guided missile,” Richards says. “Some people have responded
dramatically to this type of therapy.”
For the many who don’t respond, Richards is wondering whether combining the immune
checkpoint inhibitors with CAR T-cell therapy might work. In collaboration with Richard
Koya and other researchers at Roswell Park Cancer Institute and Cornell, she’s developing a
CAR T cell to test with dogs.
The canine clinical trial program is part of a large collaborative effort, coordinated by
Richards, to accelerate the development of therapeutics. Called PATh (Progressive
Assessment of Therapeutics), the aim is to leverage the expertise of more than 50
researchers in Ithaca and at Weill Cornell Medicine to solve a big problem in drug
development.
“Only seven percent of oncology therapies that go into human clinical trials make it out the
other side, and it’s hugely expensive and time-consuming,” Richards says. “We’re trying to
improve all levels of preclinical testing, with the idea of making it more efficient—costing
less and happening faster. As a society, we can’t sustain the current drug development
pipeline.”
PATh, Leveraging Collaborative Expertise
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“What happens when engineers, biologists, pathologists each
look at the same issue? By comparing different viewpoints, you
learn a lot. Comparative oncology is a natural fit with the radical
collaboration concept.”
Essential to improving the forecasts for drugs in human trials is better preclinical models—
dogs being one. PATh also encompasses improved mouse models from John Schimenti and
Robert Weiss, Biomedical Sciences, and collaborators at Weill Cornell Medicine. This includes
PDX mouse models, on which the cells of a human tumor can be transplanted, grown, and
treated. Ankur Singh, Sibley School of Mechanical and Aerospace Engineering, and others
from the College of Engineering, are building organoids, improved in vitro models of
cancer cells’ natural environment.
Richards hopes the PATh program will fill the gap between the high-yield, compound-
producing pharmaceutical companies and the highly-regulated human clinical trials, where
each drug in a treatment regimen has to be tested separately over the course of years. “A
pie in the sky idea is that eventually pharmaceutical companies could come to us. We could
run their top compounds through all these models—in vitro with organoids, in vivo with the
mouse models, and the super in vivo with dogs—and rapidly, in a year, be able to tell them
which ones have the best chance of success. It would tilt the odds in our favor in the human
clinical trials and make a 20-year drug development process into, maybe, a five-year one.”
Not only does the PATh program aim to bridge this gap in the drug pipeline, it also aims to
bridge the Ithaca campus with Weill Cornell Medicine in New York City. As an MD, Richards
is a part of that bridge.
An alumna of Cornell, Richards said after graduating that she never wanted to come back
to Ithaca because of the weather. “Then we were deciding where my lab should be, and I
knew we needed somebody with feet on the ground in both places. As an MD, I need to be
sitting with the DVMs. Otherwise, there’s no bridging. So Ithaca it was. And actually I spoke
too soon. I love it here.”
Richards cites the many disciplines coming together in the PATh program as well as the
tremendous resource of the College of Veterinary Medicine at large. She works with people
such as Adam Boyko, Biomedical Sciences, who is compiling a database of the genomes of
thousands of dogs. Having this kind of genetic information, in combination with known
disease susceptibilities of certain breeds, will allow Richards and others to practice precision
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medicine in dogs. Richards says that the research possibilities abound, as well as the
potential impact on human health.
“Cornell is just perfect for the kind of work I’m doing,” she adds.
Since her PhD work in Genetics at Stanford University, Richards has always been fascinated
by the commonalities between organisms, how so many genes are conserved. Looking at
disease in dogs to understand disease in humans came naturally to her, she says. “I’ve
always had this comparative philosophy, and the multidisciplinary effort at Cornell is
another way of pursuing the comparative approach. What happens when engineers,
biologists, pathologists each look at the same issue? By comparing different viewpoints, you
learn a lot,” she explains. “Comparative oncology is a natural fit with the radical
collaboration concept—that’s why it all works.”
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